Timing of stage

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%

Patients who developed CNS leukemia after hematopoietic cell transplantation had uniformly fatal outcomes, with 0% 3-year survival, compared to patients diagnosed with CNS leukemia before or at the ti

Effect: decline; 0% vs. 42% vs. 47%